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S216 Oral Presentationsunits homozygous for the CCR5-delta32 allele will provide an im-
proved probability of finding an appropriately HLA-matched donor
for a patient with HIV infection in need of a HCT.
Methods: CCR5 genotype analysis is performed on DNA extracted
from cord blood using a PCR based assay. Biomathematicians at the
NMDP developed estimates regarding the probability of providing
an adequately HLA matched cord blood unit.
Results: We have tested about 10,000 cryopreserved cord blood
units and have identified 81 homozygous CCR5-delta32 units.
Testing an additional 25,000 cord blood units from Caucasians
is expected to increase the special inventory to about 300 units
which is projected to provide for Caucasians an adequately
HLA matched cord blood unit with an adequate cell dose for
73.61% of pediatric patients and 27.92% of adults. The initial
population for transplantation is patients in need of a HCT for
a hematologic malignancy or other indication, and who are also
infected with HIV, although some selected patients with AIDS
who have no other illness may also ultimately be considered for
transplantation.
Conclusions: Cord blood transplantation has a unique role in pro-
viding for long term control or possible cure of HIV infection.
Disclosure: No relevant conflicts of interest to declare.36
LONG TERM OUTCOMES FOR ALEMTUZUMAB BASED REDUCED INTEN-
SITY CONDITIONING TRANSPLANT FOR MYELODYSPLASTIC SYN-
DROMES AND ACUTE MYELOID LEUKAEMIA
Potter, V.T., Krishnamurthy, P., Tindell, V.J., Lim, Z., Ireland, R.,
Marsh, J.C., Pagliuca, A., Ghulam,M.J. Kings College Hospital, London,
United Kingdom; United Kingdom; United Kingdom
Haematopoietic Stem Cell Transplantation (HSCT) remains
the only curative therapy for patients with myelodysplastic syn-
dromes (MDS) and acute myeloid leukaemia with tri-lineage dys-
plasia (TLD-AML). Reduced intensity conditioning (RIC) has
expanded this approach to older patients and to those with co-
morbidities. Previously published data from our institution has
shown excellent overall survival and low rates of GVHD at one
year with alemtuzumab-based RIC-HSCT. Herein we report
the long-term follow-up data of 237 patients with high risk
MDS and TLD-AML treated at our institution from 1999 to
June 2010.
All patients received a conditioning protocol consisting of fludar-
abine (150mg/m2), busulphan and alemtuzumab (100mg) from sib-
ling (n 5 57) or matched unrelated donors (MUD) (n 5 180). 30
patients received 4 days of busulphan (total dose 12.8mg/kg iv or
16mg po) while the remainder received 2 days (total dose 6.4mg/
kg iv 8mg po). The majority of patients receiving an unrelated
transplant had a fully matched donor (n 5 128), with 45 having
a 1-antigen mm donor and 7 having a 2-antigen mm donor. The
median age of the cohort was 56 years (range:19-72) and median
follow-up for survivors was 5.2 years (range:0.12-11.4). OS and
DFS for the entire cohort was 44% and 34% respectively at five years
with no significant difference between sibling andMUD transplants.
NRM was 23% at one year and 31% at five years. Relapse at five
years was 51%. Acute GVHD occurred in 35% and chronic
GVHD in 27%. The rate of extensive de-novo chronic GVHD
was very low at 10%. Outcomes were similar for those receiving
four doses of busulphan despite a higher proportion of patients not
in CR at the time of HSCT in this group.
On multivariate analysis, age remained the only significant fac-
tor with regard to OS, DFS and NRM. For patients aged less than
60 vs greater than 60 years at five years OS was 55 vs 23%, DFS
was 46 vs 15% and NRM 27 vs 50%. To our knowledge this
analysis represents the largest series of patients receiving alemtu-
zumab based RIC for MDS and TLD-AML. Long-term out-
comes remain excellent for younger patients. Novel strategies
are required for the prevention of relapse and to improve out-
comes in older patients.37
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The Myeloproliferative Disorder-Research Consortium (MPD-
RC) designed the first US prospective phase II study of reduced in-
tensity allogeneic hematopoietic stem cell transplantation (HSCT)
in patients with primarymyelofibrosis (PMF) orMF secondary to es-
sential thrombocythemia (ET-MF) or polycythemia vera (PV-MF).
Between May 2007 and March 2011, 66 patients were enrolled into
MPD-RC 101 study and transplanted from related (n5 32) or unre-
lated (n 5 34) donors using a fludarabine/melphalan 6 ATG regi-
men. Of 66 patients, 63 were at intermediate/high risk according
to Lille score system and 3 low risk patients had thrombocytopenia.
Recipients of related and unrelatedHSCTwere comparable with re-
spect to age (median: 54 vs 55 years), gender, Lille score, time from
diagnosis to transplant, presence of Jak-2 V617F mutation, spleno-
megaly and splenectomy. Donors were HLA matched in 94% of re-
lated and 74% of unrelated transplants. Engraftment of neutrophils
and platelets occurred in 31/32 related and 26/34 unrelated trans-
plants. Five secondary graft failures occurred (4 among unrelated re-
cipients). Median time to ANC . 0.5 x 109/L and platelets .20 x
109/L engraftment was: day 22 and 28 in the related, and day 18
and 28 in the unrelated cohort, respectively. Acute GVHD grade
II-IV occurred in 37% related (grade III-IV: 12%) and 42% unre-
lated transplants (grade III-IV: 21%). In patients with $ 6 months
follow-up, there were 7 CR, 8 PR, and 11 CI according to the
IWG criteria among the 28 patients in the related group, and 5
CR, 1 PR, and 5 CI among the 16 patients in the unrelated group.
After a median follow-up of 24 months for survivors in the related
group, 78% of the patients are alive, TRM was 18% and relapse-re-
lated mortality was 3%. In the unrelated group, 44% of the patients
are alive after 12months follow-up, TRMwas 53% and 3% died due
to relapse. Median survival time has not been reached in the related
group and is 7 months in the unrelated group (hazard ratio 4.2, 95%
CI: 1.7-10.1, p\0.001). Survival in unrelated transplants was not as-
sociated with PBSC or BMHSCT, HLAmatching, diagnosis, Jak-2
mutation. In this prospective study a reduced intensity allogeneic
HSCTwith Flu/Mel regimen was very effective in myelofibrosis pa-
tients transplanted from related donors. In unrelated transplants,
a high rate of primary or secondary graft failure led to a high rate
of TRM. For these patients a different conditioning regimen may
be required.38
IDENTIFICATION AND CHARACTERIZATION OF H-Y SPECIFIC ALLOGE-
NEIC B CELLS FOLLOWING SEX-MISMATCHED TRANSPLANTATION
Sahaf, B., Perloff, S.H., Wu, F., Miklos, D.B. Division of Blood andMar-
row Transplantation, Stanford University School of Medicine
H-Y allo-antibody develop in association with chronic graft-ver-
sus-host disease (cGVHD) following sex-mismatched transplant.
We hypothesize that H-Y specific B cells contribute to cGVHD
pathogenesis and have developed H-Y specific FACS stain for their
isolation and characterization.
Oral Presentations S217In order to identify the immune dominant H-Y epitope(s), we de-
veloped a high-throughput H-Y microarray. Five H-Y proteins and
their 95% identical X-chromosome homologs (H-X) were printed
on epoxy glass slides along with fifty 15-19 amino acid overlapping
disparate H-Y peptides. Normal male donors have negligible H-Y
antibodies. H-Y seropositive thresholds were mean result of 31
healthy males + 3 SD. The H-X homologue is scored using its cor-
responding H-Y antigen threshold.
Plasma samples from 32male patients with female donors (F/M)
who developed cGVHD, had sera tested for H-Y specific IgG and
IgM, 6, 12,18 months after HCT. Twenty-two of 32 (69%) had
anti-DBY (aka DDX3Y) antibodies by microarray and ELISA (R2
5 0.85). DBY-2 was recognized by 17/32 (36%) overall and ac-
counted for 77% of DBY responders.
We used this immune dominant peptide to FACS stain DBY-2
specific B cells. DBY-2 biotinylated peptide was used to capture
the antigen specific B cells and was later detected by streptavi-
dine-Qdot along with markers of B cell development. Ten healthy
males had no detectable DBY-2 staining. Peripheral blood mono-
nuclear cells (PBMCs) collected days 90, 180, 270, and 365 post
HCT from 25 F/M patients and stained for DBY-2 in relation
to DBY IgG and IgM in plasma (Table). Seven of 11 (64%) had
DBY-2 specific B cells detected as early as 90-180 days. Further,
3 of 7 (43%) of DBY and DBY-2 IgG seronegative patients tested
persistently DBY-2 B cell positive. Day 90 and 180 detected DBY-
2 B cells showed na€ıve phenotype (IgD+IgM+CD38+CD27-).
In contrast, .30% DBY-2 B cells at 1-year were activated
CD27+. The range of DBY-2 B cells at 1y was 0.3-0.8 % of
CD19+ cells.
This is the first identification of human allogeneic B cells and
surprisingly they develop months before subsequent allo-IgG and
are detected in 40-50% of seronegative F/M. Immune dominant
DBY-2 B cell isolation now enables allogeneic B cell functional
studies.
Table. H-Yantibodies and B cells detected in 32 male patients
with female donors
Protein ELISA Peptide ELISA DBY-2 B cellsF/M HCT
n 5 32 DBY IgG DBX-2 IgG DBY-2 IgM d180 d365DBY IgG
pos n 5 2222/22 (100%) 0/22 6//22 (27%) 7/11 (64%) 7/11 (64%)DBY-2 IgG
pos n 5 1712/17 (71%) 0/17 5/17 (29%) 4/11 (36%) 5/13 (39%)DBY-2 IgG
neg n 5 1510/15 (67%) 1/15 (7%) 1/17 (7%) 3/7 (43%) 4/7 (56%)Healthy Male 0/31 0/31 0/31 0/10 0/10ELISA measurements were performed 1 y after transplant.39
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The majority of patients (pts) with chronic lymphocytic leuke-
mia (CLL) with an indication for allogeneic hematopoietic cell
transplantation (HCT) suffer from refractory disease. Lower tu-
mor load prior to HCT may be associated with better outcome.
Thus, cytoreductive pre-treatment needs to be considered. Alem-
tuzumab has proven activity in refractory disease. On the other
hand, pre-treatment with alemtuzumab has been associated with
inferior outcome after HCT in a retrospective analysis. We pres-ent results from a phase II trial where we systematically investi-
gated treatment with alemtuzumab followed by a washout
period and subsequent reduced intensity conditioning (RIC) prior
to allogeneic HCT.
Methods:All pts were scheduled for onemonth of treatmentwith 30
mg alemtuzumab 3 times weekly. The washout period between the
last dose of alemtuzumab and the day of HCT was increased from
twoweeks to onemonth during the study. Antibody levels weremea-
sured on the day of HCT and T-cell engraftment was monitored.
RIC consisted of fludarabine (150 mg/m2) and busulfan (8 mg/kg).
Cyclosporine (CSA) and methotrexate (MTX) were administered
as GVHD-prophylaxis.
Results: 62 pts with relapsed or refractory CLL and a median age of
56 years were included. Two pts failed to reachHCTdue to progres-
sive disease under therapy. Donors were HLA-identical siblings (N
5 26) orHLA-compatible unrelated donors accepting onemismatch
(N 5 34). No primary or secondary graft failure occurred. Interfer-
ence of persisting antibody levels with T-cell engraftment could be
demonstrated even after a washout period of one month in 4 out of
30 pts (ASH 2009, 114:3351). The cumulative incidence of acute
GVHD grades II to IV at day +100 was 42%, and that of extensive
chronic GVHD at one year was 56%. With a median follow-up of
35 months (16 to 61 months) 3-year overall survival and progres-
sion-free survival were 62% (95% CI, 48% to 76%) and 52%
(95% CI, 38% to 66%). Day +100 non-relapse mortality was 2%.
At 3 years non-relapse mortality and relapse incidence were 24%
(95% CI, 12% to 36%) and 24% (95% CI, 13% to 35%), respec-
tively.
Conclusions:The favorable long-term results of this study argue in
favor of that strategy for patients with refractory disease. However,
unless in vivo T-cell depletion is the goal, a washout period of a min-
imum of one month after the last dose of alemtuzumab should be
kept and T-cell engraftment needs to be monitored.40
SAFETY AND EFFECTIVENESS OF INTRAVENOUS PALIVIZUMAB FOR PRE-
VENTION OF RESPIRATORY SYNCYTIAL VIRUS INFECTION FOLLOWING
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Small, T.N., Kernan, N.A., Boulad, F., Prockop, S.E., Scaradavou, A.,
Kobos, R., Zakak, N., Ruggiero, J., O’Reilly, R.J. Memorial Sloan Ketter-
ing Cancer Center, New York, NY
Respiratory syncytial virus (RSV), a single-stranded RNA virus of
the Paramyxoviridae family, is one of the most common causes of
respiratory infections during childhood. Although most children
are infected with this virus by 2 years of age resulting in the produc-
tion of neutralizing antibodies, life-long immunity is not induced.
Nosocomial spread is common, even among immunocompetent in-
dividuals. Following allogeneic HSCT, progression from upper re-
spiratory tract to lower tract disease occurs in 40-60% of cases and
is generally fatal if left untreated. In a prior study at our institution,
16 of 21 patients infected during the first post HCT month devel-
oped pneumonia. In an effort to prevent RSV infection in unrelated
and HLA-mismatched transplant recipients, intravenous palivizu-
mab (15 mg/kg infused at 20-40 mg/minute) was administered to
60 of 142 patients \21 years of age transplanted between 2005
through 2009. Patients who received prophylactic palivizumab
were younger, more likely to have been transplanted after 2007,
to be the recipient of an HLA-mismatched donor transplant,
and/or to have GVHD. Patients received a median of 3 doses of
palivizumab at 4-6 week intervals during the RSV season. All doses
were well tolerated and resulted in an RSV neutralizing antibody
titer of 1:640-.1:1280. An RSV infection developed in 6 of 60 pa-
tients who received prophylaxis and 17 of 82 who did not, (p 5
0.04). Of the 17 patients who developed RSV in the absence of pro-
phylaxis, 9 were treated with palivizumab, and none developed
pneumonia. This retrospective study demonstrates that IV palivizu-
mab is safe and suggests it can prevent infection. Future studies
evaluating the number of doses needed to prevent disease, the op-
timum population to target, and the cost effectiveness of this strat-
egy are warranted.
